Overview of the National Medical Products Administration (NMPA)

The National Medical Products Administration (NMPA), formerly known as the CFDA, is the primary regulatory authority in China responsible for the supervision and administration of drugs, medical devices, and cosmetics.

1. Regulatory Role and Responsibilities

The NMPA operates under the State Administration for Market Regulation (SAMR). Its core responsibilities regarding medical devices include:

• Formulating Regulations: Drafting laws and technical standards for medical device safety and quality.
• Review and Approval: Managing the registration of high-risk medical devices and overseeing the filing of low-risk devices.
• Supervision: Conducting inspections for Good Manufacturing Practices (GMP) and Good Supply Practices (GSP).
• Post-Market Surveillance: Monitoring adverse events, managing recalls, and ensuring whole life-cycle safety.

2. Medical Device Classification

China utilizes a three-tier risk-based classification system:

• Class I (Low Risk): Safety and effectiveness are ensured through routine administration. Requires "Record Filing" (filing) with the NMPA or local authorities.
• Class II (Moderate Risk): Requires strict control to ensure safety and effectiveness. Must undergo "Registration" at the provincial NMPA level.
• Class III (High Risk): Devices implanted in the human body or used for life support. These represent the highest risk and require "Registration" at the central NMPA level in Beijing.

3. Market Access for Imported Devices

Foreign manufacturers wishing to sell medical devices in China must:

• Appoint a Legal Agent: A Chinese entity must act as the legal agent to handle the registration and regulatory communication.
• Clinical Evaluation: Provide clinical trial data or a clinical evaluation report to prove the device's safety for the Chinese population.
• Testing: Samples may need to be tested in NMPA-certified laboratories in China to verify technical requirements.

4. Recent Developments

The NMPA has recently focused on:

• Innovative Approvals: Fast-track channels for innovative medical devices.
• Electronic Submission: Implementation of the eRPS system for digital registration.
• Online Sales Regulation: Strengthening the oversight of medical devices sold through e-commerce platforms.